FDA, U.S., has accepted PharmaEssentia’s BLA request for peginterferon alfa-2b-njft targeting Polycythemia Vera (P.V.) treatment. PharmaEssentia Corp. is based in Taiwan and has its subsidiary…
FDA, U.S., has accepted PharmaEssentia’s BLA request for peginterferon alfa-2b-njft targeting Polycythemia Vera (P.V.) treatment. PharmaEssentia Corp. is based in Taiwan and has its subsidiary…